Business
Change of Registered Address
Change of Registered Address.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 9521E ValiRx PLC 09 July 2019 \n\n \n \n \nVALIRX PLC\n(\"ValiRx\", the \"Company\" or the \"Group\")\n \nChange of Registered Address\n \nLondon, UK, 09 July 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces that its registered office address has changed to Stonebridge House, Chelmsford Road, Hatfield Heath, England, CM22 7BD with effect from today.\n \n*** ENDS ***\n \nFor more information, please contact:\n \n\n\n\nValiRx plc\n\n\nTel: +44 (0) 20 3008 4416\nwww.valirx.com\n\n\n\n\nDr Satu Vainikka, Chief Executive\n\n\nTel: +44 (0) 20 3008 4416\n\n\n\n\nTarquin Edwards, Head of Communications.\n\n\nTel: +44 (0) 7879 458 364\[email protected]\n\n\n\n\nCairn Financial Advisers LLP (Nominated Adviser) \nLiam Murray / Jo Turner / Ludovico Lazzaretti\n\n\nTel: +44 (0) 20 7213 0880\n\n\n\n\n\n\n\n\n\n\n\n\nNovum Securities Limited\nColin Rowbury\n\n\nTel: +44 (0) 20 7399 9400\n\n\n\n \nNotes for Editors\n \nAbout ValiRx \nValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in \"precision\" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.\n \nThe Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field. \n \nValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from World class institutions, such as Cancer Research UK and Imperial College. \n \nUntil recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in Va...